Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL237 in PTEN-deficient Advanced Solid Tumors
NCT06183736Phase 2Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of conpelisib in solid tumor (advanced stage), sponsored by Convalife Pharmaceutical. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
conpelisib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06183736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183736.